Hiv hcv coinfection news hcv protease inhibitors
1 / 11

- PowerPoint PPT Presentation

  • Uploaded on

HIV/HCV Coinfection News – HCV Protease Inhibitors. Juergen Rockstroh, MD Marc Poliquin, MD. Telaprevir + PegIFN/r Undetectable HCV RNA at week 12 86% TP/r vs 33% placebo Undetectable HCV RNA at week 24 74% TP/4 vs 55% placebo. Boceprevir+ PegIFN/r Undetectable HCV RNA at week 12

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about '' - arlais

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Hiv hcv coinfection news hcv protease inhibitors

HIV/HCV Coinfection News – HCV Protease Inhibitors

Juergen Rockstroh, MD

Marc Poliquin, MD

Efficacy of hcv protease inhibitors in co infected patients

Telaprevir + PegIFN/r

Undetectable HCV RNA at week 12

86% TP/r vs 33% placebo

Undetectable HCV RNA at week 24

74% TP/4 vs 55% placebo

Boceprevir+ PegIFN/r

Undetectable HCV RNA at week 12

59.4% BOC+ P/r vs. 23.5% P/r

Undetectable HCV RNA at week 24

73.4% BOC+ P/r vs. 32.4% P/r

Efficacy of HCV Protease Inhibitors in Co-Infected Patients

Dieterich D et al. Telaprevir in Combination with Pegylated Interferon--2a+RBV in HCV/

HIV-co-infected Patients: A 24-Week Treatment Interim Analysis. CROI 2012 Paper #46

Sulkowski M et al. Boceprevir + Pegylated Interferon + Ribavirin for the Treatment of

HCV/HIV-co-infected Patients: End of Treatment (Week-48) Interim Results. CROI 2012 Paper #47

Drug drug interactions with boceprevir boc
Drug-Drug Interactions with Boceprevir (BOC)

Kasserra C. et al. Clinical Pharmacology of BOC: Metabolism, Excretion, and

Drug-Drug Interactions . CROI 2011 Paper #118

Il 28b genotype and treatment response to pegifn rbv
IL-28B Genotype and Treatment Response to PegIFN-RBV

Rivero-Juarez A. et al. IL28B and the LDLr Have a Synergistic Effect on HCV Early Viral Kinetics during

the First Weeks of Treatment with Pegylated Interferon + Ribavirin in HIV/HCV-co-infected Patients.

CROI 2012 Paper #765

Predictors of non response to therapy with pegifn rbv
Predictors of Non-Response to Therapy with PegIFN-RBV

Prometheus AUROC



Prometheus Index

Available at:

iTunes App Store

Android Market

Medrano J. et al. Baseline Prediction of Response to Pegylated Interferon + Ribavirin in Chronic

HCV Using the Prometheus Score. CROI 2012 Paper #761

Il28b genotype and hcv viral load
IL28B Genotype and HCV Viral Load

Predictive values for SVR in patients infected with HCV genotype 1 (n=79).

Nuclear-STAT1, STAT1-nuclear translocation; PPV, positive predictive value; NPV, negative predictive value.

Miyamura T, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms

predict treatment outcomes in hepatitis C virus genotype 1-infected patients.

PLoS One. 2011;6(12):e28617. Epub 2011 Dec 12.

Electronic tools for assessing drug drug interactions in hiv infected patients
Electronic Tools for Assessing Drug-Drug Interactions in HIV Infected Patients

  • Online drug interaction charts

  • HIV iChart

    • iPhone & Android app

      available on iTunes and the

      Android Market

iPhone Screenshot from iTunes Store

Incidence of hcv in the swiss hiv cohort study by transmission group
Incidence of HCV in the Swiss HIV Cohort Study, by Transmission Group

Wandeler G.. et al. HCV Incidence in the SHCS: A Changing Epidemic . CROI 2012 Paper #743

2011 treatment guidelines
2011 Treatment Guidelines Transmission Group

AIDS 2011 Feb 20;25(4):399-409.

Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference.

European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel.

The role of ribavirin in treating hcv in co infected msm
The Role of Ribavirin in Treating HCV in Co-infected MSM Transmission Group

  • In group 2,

    • Sustained virological response (SVR) rates were significantly higher for peg-IFN+RBV (31 of 33) peg-IFN mono-therapy (6 of 10) (94% vs 60%, respectively; p = 0.02).

    • SVR was significantly associated with Peg-IFN+RBV combination therapy (p = 0.037) and rapid virological response (p ≤0.0001)

  • In group 1

    • SVR was only significantly associated with rapid virological response (p ≤0.0001)

Boesecke C. et al. Ribavirin Is Needed in Addition to Pegylated Interferon for Optimal

Treatment Responses in the Treatment of Acute HCV Genotype 2 and 3 Infection I

HIV-co-infected Individuals . CROI 2012 Paper #50

Repeated co infection with hcv in hiv positive msm
Repeated Co-Infection With HCV in HIV Positive MSM Transmission Group

Outcome of acute HCV according to episode number, pending patients on treatment

Ingiliz P. et al. Prior HCV Infection Does Not Protect from Sexually Transmitted HCV

Reinfection in HIV+ MSM. CROI 2012 Paper #752